Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution


Duchenne muscular dystrophy (DMD) is an X-linked progressive myopathy due to mutations in the dystrophin gene, affecting one in every 3’600–10’000 live male births. Corticosteroids are the gold standard for the treatment of DMD, as they prolonged the ambulation, diminish the need of surgery for scoliosis, and slow the progress of respiratory insufficiency and possibly cardiac dysfunction. However, chronic corticosteroid therapy increases the risk of lowering bone mineral density, exposing the patients to pain and altered quality of life.


Leave A Reply